News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly VIDEO: Key messages from the 2019 ESC EAS dyslipidaemia guidelines Targeting very high-risk patients for PCSK9 inhibition: more insights from ODYSSEY OUTCOMES EVOPACS: Evolocumab lowers LDL cholesterol without safety issues in the acute ACS setting ESC Congress 2019: Inclisiran marches on with positive results in ORION-11 ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Slide decks focusing on key results and expert analysis from FOURIER and ODYSSEY OUTCOMES – two landmark trials in PCSK9 inhibition.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

ESC Congress 2019 with World Congress of Cardiology

31 August - 4 September, Paris, France
EVOPACS: Evolocumab in acute ACS
ORION-11 with inclisiran
LDL cholesterol goals go lower…

News from EAS 2019 >

ISA2018

News from ACC 2019 >

ISA2018

Most viewed

Treatment with evolocumab avoids the use of lipoprotein apheresis in high risk patients VESALIUS-CV Looking back at 2015: what made the news? ORION-11 PCSK9 therapy- the solution to all cardiovascular disease? Greatest mortality benefit with highest LDL cholesterol above 100 mg/dl VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) PCSK9 inhibitors in the clinic: New analyses provide clarification on long-term treatment issues VIDEO: New insights from ODYSSEY OUTCOMES ANITSCHKOW

Most viewed

Treatment with evolocumab avoids the use of lipoprotein apheresis in high risk patients

Hot Topics

PCSK9 inhibitors work – but access is the problem

Prof Chris Packard (University of Glasgow, UK)
The take home message from this US study: A high absolute risk reduction (in high-risk patients with high LDL-C) is paramount to the cost effectiveness of PCSK9 inhibitors.

Read the Report

Recent Hot Topics:

Prof Børge Nordestgaard: Lipoprotein(a): a therapeutic target in guidelines?
Listen to the presentation
Prof Raul Santos: Coronary artery calcium in familial hypercholesterolaemia Read the Report

From the Editors

Targeting PCSK9 inhibitors to the right patient

Professor Stephen J Nicholls (Monash University, Melbourne, Australia)

FOURIER and ODYSSEY OUTCOMES clearly demonstrate that PCSK9 inhibitors reduce cardiovascular events. The question is: How do we target PCSK9 inhibition to very high risk patients most likely to benefit?

Read the report
Watch the video

Professor Derick Raal: LDL cholesterol goals in patients with diabetes – How low?
Read the report